Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is regarded as a curative therapy for majority of hematologic malignancies and some non-malignant hematologic diseases. Venous thromboembolism (VTE) has become increasingly recognized as a severe complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Objectives: To show the characteristics of VTE after haploidentical donor hematopoietic stem cell transplantation (HID-HSCT) and make comparisons with matched related donor HSCT (MRD-HSCT).
Patients/methods: A retrospective nested case-control study design was used, cases with VTE and matched controls were selected, with 3534 patients underwent HID-HSCT and 1289 underwent MRD-HSCT.
Results: During follow-up, 114 patients with VTE were identified. The incidence of VTE in HID-HSCT group was similar to that of MRD-HSCT group (2.4% versus 2.3%, P = 0.92). In HID-HSCT group, VTE occurred at a median time of 92.5 days, which was earlier than MRD-HSCT group (243.5 days). For HID-HSCT, advanced disease status, cardiovascular risk factors, acute graft-versus-host disease (aGVHD), and relapse were the independent risk factors for VTE. For MRD-HSCT, cardiovascular risk factors, aGVHD, and relapse were associated with VTE. Overall survival (OS) of patients following HID-HSCT and MRD-HSCT were similar, but the OS in patients with VTE was significantly lower than patients without VTE.
Conclusions: There was no statistical difference in the incidence of VTE after HID-HSCT compared with MRD-HSCT. The development of VTE adversely impacted the OS after allo-HSCT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2020.06.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Zebrafish ETS transcription factor Fli1b functions upstream of Scl/Tal1 during embryonic hematopoiesis.
Biol Open
March 2025
Department of Pathology and Cell Biology, USF Health Heart Institute, University of South Florida, Tampa, FL 33602, USA.
During embryonic development vascular endothelial and hematopoietic cells are thought to originate from a common precursor, the hemangioblast. An evolutionarily conserved ETS transcription factor FLI1 has been previously implicated in the hemangioblast formation and hematopoietic and vascular development. However, its role in regulating hemangioblast transition into hematovascular lineages is still incompletely understood.
View Article and Find Full Text PDFImplementation of a novel hybrid cord blood banking model within a private-public-partnership.
Transfusion
March 2025
Department of Obstetrics and Gynecology, University Hospital of Bern, University of Bern, Bern, Switzerland.
Background: Umbilical cord blood (UCB) stem cells can be collected at birth, cryopreserved, and used for transplantation in hematopoietic diseases. Typically, these stem cells are stored in public banks for allogeneic use or in private depositories for potential future utilization by the family. A proposed third option, hybrid cord blood banking, combines elements of both public and private storage.
View Article and Find Full Text PDFEnforcement of stem-cell dormancy by nucleophosmin mutation is a critical determinant of unrestricted self-renewal during myeloid leukemogenesis.
Haematologica
March 2025
Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan.
Mutations in the NPM1 gene (NPMc+) and in the FLT3 gene (FLT3-ITD) represent the most frequent co-occurring mutations in Acute Myeloid Leukemia (AML), yet the cellular and molecular mechanisms of their cooperation remain largely unexplored. Using mouse models that faithfully recapitulate human AML, we investigated the impact of these oncogenes on pre-leukemic and leukemic hematopoietic stem cells (HSCs), both separately and in combination. While both NPMc+ and Flt3-ITD promote the proliferation of pre-leukemia HSCs, only NPMc+ drives extended selfrenewal by preventing the depletion of the quiescent HSC pool.
View Article and Find Full Text PDFCombination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study.
Front Immunol
March 2025
Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory/relapsed B cell non-Hodgkin's lymphoma (R/R B-NHL) in remission after second-line chemotherapy or salvage therapy. However, patients with different pathological subtypes and remission states may benefit differently from ASCT or CAR-T cell therapy. Furthermore, consolidation treatment involving ASCT or CAR-T cells still poses a significant risk of disease relapse.
View Article and Find Full Text PDFCombined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with mutation: A case report.
SAGE Open Med Case Rep
March 2025
Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, P. R. China.
Despite advancements in the treatment of diffuse large B-cell lymphoma, including CAR T-cell therapy, mutations remain a significant negative prognostic factor in patients with relapsed/refractory diffuse large B-cell lymphoma. The combination of autologous stem cell transplantation and CAR T-cell therapy may enhance long-term prognosis and reduce adverse effects, including severe cytokine release syndrome. This case report presents a 41-year-old man with relapsed/refractory diffuse large B-cell lymphoma harboring mutations who underwent autologous stem cell transplantation combined with CD19 CAR T-cell therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!